Latest News

Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

Jan

20

2022

Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma

Dec

16

2021

Senhwa Clinical Data Abstract for Silmitasertib in Patients with Advanced Basal Cell Carcinoma Accepted for 2022 AAD Annual Meeting

Dec

14

2021

Senhwa Biosciences Announces Abstract Accepted for Presentation at the 2022 ASCO Gastrointestinal Cancers Symposium

Nov

15

2021

Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference

Oct

20

2021

Senhwa’s Pidnarulex to Combined With Pfizer’s Talazoparib in a Clinical Trial for the Treatment of Prostate Cancer

Sep

22

2021

Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations

Sep

10

2021

Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

Aug

31

2021